More

    Japan Approves COVAXIN booster dose for Travelers; reinforces the effectiveness of Universal Covid Vaccine

    Japan on Friday accorded approval for Bharat Biotech’s Covaxin booster dose for travellers. In April this year, the nation included the Made-in-India Covid-19 vaccine in the list of recognised vaccines. And, now (August 5), Japan has also approved the booster shot of Covaxin.

    Bharat Biotech wrote in a statement, “We are proud to announce, Japan has approved COVAXIN booster dose for travellers”.

    Earlier this month, the vaccine developer announced that the administration of the third dose of its Covid-19 vaccine Covaxin (BBV152) after six months of two-dose vaccination significantly enhanced neutralizing antibody responses, and demonstrated increased memory B cell response in subjects in controlled clinical trials.

    The findings published in a peer review journals were based on a comprehensive study that has demonstrated multiple benefits of Covaxin. According to Bharat Biotech the vaccine provides benefits like long-term immune response, cell-mediated immunity, the safety of booster dose, and immunogenicity against spike protein.

    The biotech major also said immune responses declined at six months but increased by 40-fold in subjects who received a booster dose. Immune responses when assessed against variants of concern and persisted up to 12 months.

    Covaxin is a multi-epitome vaccine – Dr. Krishna Ella

    Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Our team has now demonstrated that Covaxin is a multi-epitope vaccine with antibodies against spike, RBD, and N proteins. Post booster dose, it has proven to neutralize antibody responses against variants of concern and long-term protection through memory T and B cell responses. We have now achieved our goal of developing a safe and efficacious vaccine with long-term protection against a spectrum of variants.”

    The study was conducted on 184 subjects, who were randomized 1:1 and received either a booster dose of BBV152 or a placebo, 6 months after the primary series of two doses. Subjects were evaluated for safety, neutralizing antibody responses against variants of concern, binding antibodies against spike protein, RBD, and N proteins, and for memory T and B cell responses to demonstrate cell-mediated immunity, said the company.

    Share

    Latest Updates

    Related Articles

    Vizag Tech Summit 2023 announces INR 3000 Cr Projected Investments

    The Vizag Tech Summit 2023 will be held on February 16th and 17th, 2023...

    iNCOVACC Fast Facts: World’s first Intranasal vaccine approved by India

    Bharat Biotech iNCOVACC®️ (BBV154), has received approval from the Central Drugs Standard Control Organisation...

    China’s Foxconn’s factory unrest may lead to serious shortage of iPhone’s

    Foxconn's factory in Zhengzhou, China, is experiencing employee unrest that could lead to a...

    Fear of T20 taking away the best players plagues international cricket

    T20 Cricket is threating national teams globally as players seem to prefer playing T20...